Suven Life Sciences, the Rs 625 crore pharmaceutical company, provides contract research and manufacturing services to global life sciences companies. It will reportedly invest 75 million dollars (about Rs 520 crore) in the new business.
Under the process, Shore Suven Pharma's purchase agreement served as the stalking horse agreement and an auction would have been conducted had the company received qualified offers from other bidders reflecting potentially higher or better terms.
No such bids were received prior to the bid deadline. Thus no auction was conducted and Shore Suven Pharma was selected as the successful bidder for Rising Pharmaceuticals on March 29, the company said in a statement.
The transaction is expected to close on April 19.
Suven Life Sciences CEO Venkat Jasti said the court approval brings closure to the sale process for Rising Pharmaceuticals.
"It paves the way for a seamless transition of the portfolio, customer programmes and manufacturing and drug development relationships to Shore Suven Pharma Inc, which in turn will pave the way for continuity of product supply to the customers," he said.
Shore Suven Pharma Inc's CEO Vimal Kavuru said the acquisition of Rising's assets will transform Shore Suven Pharma into a strong US generic pharmaceutical company.
"Leveraging Rising's extensive product portfolio and vertically integrating with Suven's world-class active pharmaceutical ingredient (API) and finished dose manufacturing capabilities will enable us to better serve US customers," he said.